Please wait a minute...
Journal of Molecular and Clinical Medicine   2019, Vol. 2 Issue (2): 23-28    DOI: 10.31083/j.jmcm.2019.02.9161
Original Research | Next articles
Retinoids offer new and promising cancer therapeutic avenues
Xin Cao1, Quanlin An1, Yehuda G. Assaraf2, *(), Xiangdong Wang1, *()
1 Zhongshan Hospital Institute of Clinical Science, Fudan University Shanghai Medical College, Shanghai 200032, P. R. China
2 The Fred Wyszkowski Cancer Research Lab, Faculty of Biology, Technion-Israel Institute of Technology, Haifa 3200000, Israel
Download:  PDF(407KB)  ( 51 ) Full text   ( 20 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

All trans-retinoic acid (ATRA) as well as several key retinoids including tamibarotene, acyclic retinoid (ACR), and WYC-209, have made a major progress in both pre-clinical cancer therapeutics as well as in the clinical setting regarding the treatment of leukemia and solid tumors via their important impacts on cancer stem cell differentiation or apoptosis. ATRA exerts its antitumor activity by binding to retinoic acid receptors, which in turn specifically bind to DNA as a heterodimer with the retinoid X receptors, at promoter regions known as retinoic acid response elements. The impressive new studies and clinical achievements with retinoids as key pre-clinical research tools and antitumor agents, are summarized and discussed in the current paper. The ongoing clinical trial of tamibarotene, which is the first agent targeting super-enhancers-containing cancers, could provide a new treatment modality for acute myeloid leukemia patients. A recent clinical study for evaluation of the preventive effects of ACR on second primary hepatocellular carcinoma (HCC) demonstrated that the oral administration of ACR for 12 months, significantly reduced HCC recurrence. WYC-209 strongly inhibited cell proliferation of different tumor repopulating cells (TRCs), a highly tumorigenic subpopulation of mouse melanoma cells, and also blocked > 80% of B16 TRCs' lung metastases in wild-type C57BL/6 mice, without any apparent toxicity. These remarkable findings reveal that retinoids constitute a promising class of antitumor agents for the treatment of both hematological malignancies and solid tumors.

Key words:  Retinoids      cancer therapy      cancer stem cells      differentiation      apoptosis     
Published:  20 April 2019     
*Corresponding Author(s):  Yehuda G. Assaraf; Xiangdong Wang     E-mail:  assaraf@technion.ac.il; xiangdong.wang@clintransmed.org

Cite this article: 

Xin Cao, Quanlin An, Yehuda G. Assaraf, Xiangdong Wang. Retinoids offer new and promising cancer therapeutic avenues. Journal of Molecular and Clinical Medicine , 2019, 2(2): 23-28.

URL: 

https://jmcm.imrpress.com/EN/10.31083/j.jmcm.2019.02.9161     OR     https://jmcm.imrpress.com/EN/Y2019/V2/I2/23

Figure 1.  Vitamin A metabolic pathway and important retinoids in advanced cancer research and therapy. Vitamin A is converted to retinal via oxidation by retinol dehydrogenases; while retinal is converted to ATRA via further oxidation by retinaldehyde dehydrogenases. The important retinoids in advanced cancer research and therapy include ATRA, tamibarotene, acyclic retinoid, and WYC-209.

Table 1.  Retinoids in recent cancer treatments and advanced cancer research
Retinoids Company Targets Stage Cancer Indications Side effects
Tretinoin
(ATRA)
Triax Pharm, etc pan-RAR/RXR
agonist
Launched Acute promyelocytic leukemia (APL) Liver dysfunction, heart rhythm abnormalities, intestinal toxicity, etc [6, 7]
Tamibarotene Nippon Shinyaku,
Syros Pharma
RARα/β agonist Launched;
Phase II,
NCT02807558 (US)
Recurrent acute promyelocytic leukemia (APL)
Acute Myeloid Leukemia (AML)
Side effects were similar but milder than those of ATRA [8, 9]
Peretinoin
(Acyclic retinoid)
Kowa Pharm pan-RAR/RXR
agonist
Phase III, NCT01640808 (US) Hepatic Neoplasm Malignant Recurrent Side effects were similar but milder than those of ATRA [10, 11]
WYC-209 Baiyu Pharm RAR modulator Pre-clinical Melanoma metastases, hepatocellular carcinoma (HCC) Unclear [12]
Figure 2.  The docking mode of WYC-209 on RARβ (PDB:1XAP, Gold Suite 5.0). The double H-bonds formed between the oxygen atoms of the carboxyl group of WYC-209 and Arg269/Ser280 of RARβ, may play key roles in functional modulation of RARα/β activity.

[1] DeLuca Luca LM. Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB Journal, 1991; 5: 2924-2933.
pmid: 1661245
[2] Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nature Reviews Drug Discovery, 2007; 6: 793-810.
doi: 10.1038/nrd2397 pmid: 17906642
[3] Dominguez M, Alvarez S, de Lera AR. Natural and structure-based RXR ligand scaffolds and their functions. Current Topics in Medicinal Chemistry, 2017; 17: 631-662.
doi: 10.2174/1568026616666160617072521 pmid: 27320335
[4] Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis, 2000; 21: 1271-1279.
pmid: 10874003
[5] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011; 144: 646-674.
doi: 10.1016/j.cell.2011.02.013
[6] Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Wiernik PH. All-trans-retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine, 1997; 337: 1021-1028.
doi: 10.1056/NEJM199710093371501 pmid: 9321529
[7] Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, Luo M, You MH, Yao Y, Kondo A, Hu H, Bozkurt G, Moerke NJ, Cao S, Reschke M, Chen CH, Rego EM, Lo-Coco F, Cantley LC, Lee TH, Wu H, Zhang Y, Pandolfi PP, Zhou XZ, Lu KP. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nature Medicine, 2015; 21: 457-466.
doi: 10.1038/nm.3839 pmid: 25849135
[8] McKeown MR, Corces MR, Eaton ML, Fiore C, Lee E, Lopez JT, Chen MW, Smith D, Chan SM, Koenig JL, Austgen K, Guenther MG, Orlando DA, Lovén J, Fritz CC, Majeti R. Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. Cancer Discovery, 2017; 7: 1136-1153.
doi: 10.1158/2159-8290.CD-17-0399 pmid: 28729405
[9] Ledford H. Cancer researchers seek to harness mysterious DNA super-enhancers. Nature, 2018; 564: 173-174.
doi: 10.1038/d41586-018-07602-8 pmid: 30531879
[10] Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. New England Journal of Medicine, 1996; 334: 1561-1567.
doi: 10.1056/NEJM199606133342402 pmid: 8628336
[11] Kada N, Suzuki T, Aizawa K, Matsumura T, Ishibashi N, Suzuki N, Takeda N, Munemasa Y, Sawaki D, Ishikawa T, Nagai R. Acyclic retinoid inhibits neointima formation through retinoic acid receptor beta-induced apoptosis. Arteriosclerosis Thrombosis and Vascular Biology. 2007; 27: 1535-1541.
doi: 10.1161/ATVBAHA.106.134114 pmid: 17478760
[12] Chen JW, Cao X, An QL, Zhang Y, Li K, Yao WT, Shi FC, Pan YF, Jia Q, Zhou WW, Yang F, Wei FX, Wang N, Yu B. Inhibition of cancer stem cell like cells by a synthetic retinoid. Nature Communications, 2018; 11: 1406.
doi: 10.1038/s41467-018-03877-7 pmid: 29643385
[13] de Thé H. Differentiation therapy revisited. Nature Reviews Cancer, 2018; 18: 117-127.
doi: 10.1038/nrc.2017.103 pmid: 29192213
[14] Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the european leukemia net. Blood, 2019; 133: 1630-1643.
doi: 10.1182/blood-2019-01-894980 pmid: 30803991
[15] Iland HJ. Curative strategies in APL. Seminars in Hematology, 2019; 56: 131-138.
doi: 10.1053/j.seminhematol.2018.07.004 pmid: 30926089
[16] Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. Journal of Medicinal Chemistry, 1988; 31: 2182-2192.
doi: 10.1021/jm00119a021 pmid: 3184125
[17] Tamura K, Kagechika H, Hashimoto Y, Shudo K, Ohsugi K, Ide H. Synthetic retinoids, retinobenzoic acids, Am80, Am580 and Ch55 regulate morphogenesis in chick limb bud. Cell Differentiation and Development, 1990; 32: 17-26.
doi: 10.1016/0922-3371(90)90095-e pmid: 2090329
[18] Ono T, Tamaoka T, Yuasa Y. Reaction of alpha-(phenylsulfinyl)acetonitrile with aldehydes and ketones to gamma-hydroxyalkenenitriles and syntheses of terpenoids. Journal of the American Chemical Society, 1984; 106: 7890-7893.
doi: 10.1021/ja00337a042
[19] Shafritz DA. Synthetic retinoids for the secondary prevention of hepatocellular carcinoma. New England Journal of Medicine, 1996; 334: 1600-1601.
doi: 10.1056/NEJM199606133342410 pmid: 8628344
[20] Decensi A, Costa A. Polyprenoic acid in hepatocellular carcinoma. New England Journal of Medicine, 1996; 335: 1461-1462.
pmid: 8927082
[21] Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature Reviews Gastroenterology & Hepatology, 2019; 16: 589-604
doi: 10.1038/s41575-019-0252-5 pmid: 31822823
[22] de' Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World Journal of Gastroenterology, 2015; 21: 11185-11198.
doi: 10.3748/wjg.v21.i39.11185 pmid: 26494973
[23] Shirakami Y, Sakai H, Shimizu M. Retinoid roles in blocking hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2015; 4: 222-228.
doi: 10.3978/j.issn.2304-3881.2015.05.01 pmid: 26311412
[24] Qin XY, Suzuki H, Honda M, Okada H, Kaneko S, Inoue I, Ebisui E, Hashimoto K, Carninci P, Kanki K, Tatsukawa H, Ishibashi N, Masaki T, Matsuura T, Kagechika H, Toriguchi K, Hatano E, Shirakami Y, Shiota G, Shimizu M, Moriwaki H, Kojima S. Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. Proceedings of the National Academy of Sciences, 2018; 115: 4969-4974.
doi: 10.1073/pnas.1802279115 pmid: 29686061
[25] Lehmann-Che J, Bally C, de Thé H. Therapy resistance in APL. New England Journal of Medicine, 2014; 371: 1171-1172.
doi: 10.7534/j.issn.1009-2137.2019.06.052 pmid: 31839078
[26] Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer, 2013; 13: 714-726.
doi: 10.1038/nrc3599
[27] Liu J, Tan Y, Zhang H, Zhang Y, Xu P, Chen J, Poh YC, Tang K, Wang N, Huang B. Soft fibrin gels promote selection and growth of tumorigenic cells. Nature Materials, 2012; 11: 734-741.
doi: 10.1038/NMAT3361
[28] Tan Y, Tajik A, Chen J, Jia Q, Chowdhury F, Wang L, Chen J, Zhang S, Hong Y, Yi H, Wu DC, Zhang Y, Wei F, Poh YC, Seong J, Singh R, Lin LJ, Doğanay S, Li Y, Jia H, Ha T, Wang Y, Huang B, Wang N. Matrix softness regulates plasticity of tumour-repopulating cells via H3K9 demethylation and Sox2 expression. Nature Communications, 2014; 5: 4619.
doi: 10.1038/ncomms5619 pmid: 25099074
[29] Germain P, Kammerer S, Perez E, Peluso-Iltis C, Tortolani D, Zusi FC, Starrett J, Lapointe P, Daris JP, Marinier A, De Lera AR, Rochel N, Gronemeyer H. Rational design of RAR-selective ligands revealed by RARbeta crystal structure. Embo Reports, 2004; 5: 877-882.
doi: 10.1038/sj.embor.7400235 pmid: 15319780
[30] Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 1997; 3: 730-737.
doi: 10.1038/nm0797-730 pmid: 9212098
[31] Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nature Reviews Cancer, 2008; 8: 755-768.
doi: 10.1038/nrc2499 pmid: 18784658
[32] Cao X. Retinoids Induced Cancer Stem Cell Differentiation and Apoptosis for Cancer Therapies. Molecular and Cellular Therapy, 2019; 7: 1-8.
doi: 10.1126/scitranslmed.aao4680 pmid: 29769286
[1] Xiaoli Hua, Yi Wang, Chunbo Yang, Ruifeng Chai, Xiang Li, Gulifeire Tayier, Pengfei Pan, Xiangyou Yu. Effect of incubation with lipopolysaccharide and interferon-γ on reactive astrogliosis[J]. Journal of Molecular and Clinical Medicine , 2019, 18(4): 415-421.
[2] Qiong Zhou, Yangfang An, Yonghong Tang. Long noncoding RNA-regulator of reprogramming alleviates hypoxia-induced cerebral injury in mice model and human via modulating apoptosis complexes[J]. Journal of Molecular and Clinical Medicine , 2019, 18(4): 431-437.
[3] Junmin Chen, Na Liu, Xiaopeng Wang, Yanying Zhao, Junna He, Lan Yang, Qian Sun, Jing Zhao, Linjing Wang, Lei Chen. Dl-3-n-butylphthalide inhibits phenytoin-induced neuronal apoptosis in rat hippocampus and cerebellum[J]. Journal of Molecular and Clinical Medicine , 2019, 18(3): 277-283.
[4] Dapeng Zhu, Caixing Sun, Xiang Qian. MST1 suppresses viability and promotes apoptosis of glioma cells via upregulating SIRT6 expression[J]. Journal of Molecular and Clinical Medicine , 2019, 18(2): 117-126.
[5] Zhixiong Zhang, Rong Li, Xiaoyan Zhang, Yaxuan Wei, Hongbing Ma, Ling Zhu, Rong Yin. Voluntary exercise promotes neurotrophic factor and suppresses apoptosis in hippocampal ischemia[J]. Journal of Molecular and Clinical Medicine , 2019, 18(1): 65-70.
No Suggested Reading articles found!